Day: November 9, 2025
Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor UpdateFaraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: FX Super One Planned to Enter the Pilot Build and Production Phase at its Hanford Manufacturing Facility as First Batch of Complete Sets of Parts Scheduled to Arrive in the U.S. as Early as this Month.FF Recently Filed a Utility Patent Application for a Blockchain-and-Web3-Based Car Sharing and Short-Term Rental System.FF is scheduled to report its third quarter financial results for 2025 after market close on Thursday, November 13, 2025, and will hold an earnings call at 4:30 p.m. Pacific Time (7:30 p.m. Eastern Time) that same day.LOS ANGELES, Nov. 09, 2025 (GLOBE NEWSWIRE) — Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”),...
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
Written by Customer Service on . Posted in Public Companies.
DUBLIN and BRIDGEWATER, N.J., Nov. 09, 2025 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today highlighted a new post hoc analysis of aspirin use in REDUCE-IT® reinforcing that icosapent ethyl significantly reduced cardiovascular (CV) events in high-risk patients. These findings highlight the importance of guideline-directed therapies and further validate the role of icosapent ethyl in comprehensive CV risk management in appropriate patients as studied in REDUCE-IT. This analysis was presented soon after the U.S. Food and Drug Administration (FDA) updated labeling for fenofibrate (fibrates) products that now include language on the neutral PROMINENT trial, reinforcing the lack of CV benefit when fibrates were used alongside statins for cardiovascular...
RadNet Reports Third Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA¹ and Revises Upwards 2025 Financial Guidance Ranges
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Total Company Revenue increased 13.4% to $522.9 million in the third quarter of 2025 from $461.1 million in the third quarter of 2024; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 51.6% to $24.8 million in the third quarter of 2025 from $16.4 million in the third quarter of 2024
Total Company Adjusted EBITDA(1) was $84.9 million in the third quarter of 2025 as compared with $73.7 million in the third quarter of 2024, an increase of 15.2%; Digital Health reportable segment Adjusted EBITDA(1) increased 6.9% to $3.5 million in the third quarter of 2025 from $3.2 million in the third quarter of 2024
Total Company Adjusted EBITDA(1) margins increased by 26 bps to 16.2% in the third quarter of 2025 as compared with 16.0% in the third quarter of 2024
Adjusting for unusual or one-time items...
AHA 2025: Late-Breaking Data Reinforce the Prognostic Power of AI-Driven Heartflow Plaque Analysis as the Most Clinically Validated Framework for Coronary Risk Stratification
Written by Customer Service on . Posted in Public Companies.
Multicenter outcomes FISH&CHIPS study of nearly 8,000 patients confirms total plaque volume as a powerful independent predictor of long-term cardiovascular eventsHeartflow Plaque Staging Personalizes Individual Cardiac Risk*Heartflow Plaque Analysis is an FDA-cleared device. Heartflow Plaque Staging is an investigational only framework and its safety and effectiveness have not been reviewed by the FDA.Overall Considerations3. Tzimas, et al. JACC. 2023. https://doi.org/10.1016/j.jcmg.2023.05.011NEW ORLEANS, Nov. 09, 2025 (GLOBE NEWSWIRE) — Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced late-breaking data from the FISH&CHIPS Study presented at the American Heart Association (AHA) Scientific Sessions 2025. The new data add to the...
Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD – The Liver Meeting® 2025
Written by Customer Service on . Posted in Public Companies.
WILMETTE, Ill., Nov. 09, 2025 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, is presenting new data and analyses today from the Phase 2 ALXN1840-WD-204 copper balance study at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2025, taking place in Washington, D.C., from November 7-11, 2025.
In an oral presentation titled “Rapidly Improved Cu Balance in Wilson Disease Patients on Tiomolybdate Choline,” Professor Aftab Ala, MBBS, M.D., FRCP, Ph.D., Professor of Hepatology and Consultant Hepatologist at the Institute of Liver Studies at King’s College Hospital in London, will be sharing results showing that treatment with ALXN1840 (tiomolybdate...
CNH introduces FLEETPRO aftermarket line-up at Agritechnica 2025
Written by Customer Service on . Posted in Public Companies.
CNH FLEETPROCNH introduces FLEETPRO aftermarket line-up at Agritechnica 2025CNH introduces FLEETPRO aftermarket line-up at Agritechnica 2025A new spare parts and consumables certified portfolio
Precision Technology service kit updatesHanover, November 9, 2025
CNH (NYSE: CNH), a global leader in agricultural equipment, technology and services, is introducing its FLEETPRO line-up of aftermarket services at Agritechnica 2025.
The FLEETPRO line-up includes a portfolio of certified spare parts and consumables for agricultural equipment, mainly recommended for post-warranty and legacy agricultural machinery. This delivers customers with additional support by providing dependable performance and tailored dealer support at a competitive price point. It is available across Europe, the Middle East, and Africa (EMEA).
An enhanced...
